Disease burden of congenital cytomegalovirus infection in Japan

Aoki, Hirosato; Kitano, Taito; Kitagawa, Daisuke

doi:10.1016/j.jiac.2020.08.018

Cited by 6 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In short, universal newborn CMV screening is required for ensuring efficient evaluation of infected newborns, consideration of treatment, and appropriate follow-up care. Given the enormous public health burden and disability costs [65], newborn CMV screening appears to be cost-effective as well as medically beneficial [66][67][68]. Challenges to the implementation of universal newborn CMV screening programs include the poor sensitivity of DBS CMV PCR [69] and the fact that urine or saliva samples are currently not routinely collected at birth.…”

Section: Newborn Ccmv Screeningmentioning

confidence: 99%

Perinatal Cytomegalovirus Infection

Carmona

Kakkar

Gantt

2022

Curr Treat Options Peds

View full text Add to dashboard Cite

Purpose of review There have been recent advances in the field of congenital CMV infection (cCMV) related to antiviral treatment of pregnant women and infants, the implementation of newborn CMV screening programs, and the frequency and diagnosis of complications among infected children. In addition, postnatal CMV infection (pCMV) is increasingly recognized as a potential cause of long-term sequelae in addition to acute complications among preterm infants, raising important questions related to treatment, and prevention. Recent findings High-dose valacyclovir appears to be safe and effective for the prevention of cCMV among women with first-trimester primary CMV infection. New studies reveal high rates of vestibular dysfunction and neuropsychiatric manifestations among children with cCMV. Some studies report associations between pCMV and long-term consequences, including neurodevelopmental delay and bronchopulmonary dysplasia, among very low birth weight infants, in addition to high risk of sepsis and death acutely, which has motivated efforts to eliminate the virus from breast milk by different methods. Summary More long-term complications of cCMV are increasingly recognized among children previously thought to be asymptomatic. Although a preventive CMV vaccine may be achievable, strategies to reduce the burden of cCMV disease include maternal education about risk-reduction behaviors, antiviral treatment of pregnant women with primary infection, and newborn screening to allow timely, appropriate care. Similarly, although it remains unclear if pCMV causes long-term problems, there is growing interest in identifying and preventing disease from CMV infections among preterm infants.

show abstract

Section: Newborn Ccmv Screeningmentioning

confidence: 99%

Perinatal Cytomegalovirus Infection

Carmona

Kakkar

Gantt

2022

Curr Treat Options Peds

View full text Add to dashboard Cite

show abstract

“…Disease burden data has the characteristics of high capacity, rapid growth, diverse types, and low value density [ 23 ]. Some scholars have examined a lot of high-quality research in the field of disease burden [ 24 – 26 ]. Therefore, the technological breakthrough of big data in disease burden research is very important.…”

Section: Introductionmentioning

confidence: 99%

Design and Development of a Big Data Platform for Disease Burden Based on the Spark Engine

Gao

Qing

et al. 2023

Computational Intelligence and Neuroscience

View full text Add to dashboard Cite

Objective. This study attempts to build a big data platform for disease burden that can realize the deep coupling of artificial intelligence and public health. This is a highly open and shared intelligent platform, including big data collection, analysis, and result visualization. Methods. Based on data mining theory and technology, the current situation of multisource data on disease burden was analyzed. Putting forward the disease burden big data management model, functional modules, and technical framework, Kafka technology is used to optimize the transmission efficiency of the underlying data. This will be an efficient and highly scalable data analysis platform through embedding embedded Sparkmlib in the Hadoop ecosystem. Results. With the concept of “Internet + medical integration,” the overall architecture design of the big data platform for disease burden management was proposed based on the Spark engine and Python language. The main system composition and application scenarios are given at four levels: multisource data collection, data processing, data analysis, and the application layer, according to application scenarios and use requirements. Conclusion. The big data platform of disease burden management helps to promote the multisource convergence of disease burden data and provides a new path for the standardized paradigm of disease burden measurement. Provide methods and ideas for the deep integration of medical big data and the formation of a broader standard paradigm.

show abstract

“…Approximately 300,000 babies born in Japan each year are at risk of congenital CMV infection [ 3 ], and around 1 in 1000 live births in Japan result in congenital CMV infection-related disability, which is similar to the incidence of Down syndrome [ 3 ]. Accordingly, the annual economic burden of congenital CMV infection in Japan was estimated to be JPY 27.6 billion in 2019, predominantly due to the social costs associated with congenital infection [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study

et al. 2023

View full text Add to dashboard Cite

Cytomegalovirus (CMV) infection can cause newborn morbidity and mortality; no pharmacological method of reducing CMV infection during pregnancy is currently available. In a phase 1 study in the United States, V160, a conditionally replication-defective CMV vaccine, was immunogenic and well tolerated. This placebo-controlled study (NCT03840174) investigated the safety and immunogenicity of a three-dose V160 vaccine administered over six months. A total of 18 healthy adult Japanese males (9 seronegative and 9 seropositive) were enrolled at a single center and randomized 2:1 to intramuscular V160 or placebo. In vitro, V160 induced high CMV-specific neutralizing antibody (NAb) titers (50% neutralization titer [NT50], 3651; 95% confidence interval [CI], 1688–7895) in the CMV-seronegative per-protocol immunogenicity (PPI) population one month after the third vaccine dose was administered compared with no change in the placebo arm (NT50, <94; 95% CI <94–115). The geometric mean titer ratio in the seronegative population versus baseline was 77.7 (95% CI, 23.9–252.4). CMV NAb titers in the CMV-seropositive PPI population were similar to baseline NAb titers observed in the CMV-seropositive population. V160 was well tolerated, and no vaccine viral DNA shedding was observed. In conclusion, the immunogenicity and safety profile of V160 in Japanese participants was consistent with other populations.

show abstract

Disease burden of congenital cytomegalovirus infection in Japan

Cited by 6 publications

References 32 publications

Perinatal Cytomegalovirus Infection

Perinatal Cytomegalovirus Infection

Design and Development of a Big Data Platform for Disease Burden Based on the Spark Engine

Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study

Contact Info

Product

Resources

About